Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer

Malou C.P. Kuppen; H.M. (Hans) Westgeest; Maarten J. Van Der Doelen; Alphonsus J.M. Van Den Eertwegh; Jules L.L.M. Coenen; Katja K.H. Aben; Alphons C.M. Van Den Bergh; Andries M. Bergman; Joan Van Den Bosch; Filiz Celik; Mathijs P. Hendriks; Jules Lavalaye; Saskia Van Der Meer; Marco B. Polee; Diederik M. Somford; Inge M. Van Oort; Carin A. Uyl-De Groot; Winald R. Gerritsen

doi:10.2217/fon-2020-0039

Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer

Malou C.P. Kuppen^*
, H.M. (Hans) Westgeest
, Maarten J. Van Der Doelen
, Alphonsus J.M. Van Den Eertwegh
, Jules L.L.M. Coenen
, Katja K.H. Aben
, Alphons C.M. Van Den Bergh
, Andries M. Bergman
, Joan Van Den Bosch
, Filiz Celik
, Mathijs P. Hendriks
, Jules Lavalaye
, Saskia Van Der Meer
, Marco B. Polee
, Diederik M. Somford
, Inge M. Van Oort
, Carin A. Uyl-De Groot
, Winald R. Gerritsen

^*Corresponding author for this work

Health Technology Assessment (HTA)

Research output: Contribution to journal › Article › Academic › peer-review

39 Citations (Scopus)

Abstract

Aim: Timing of radium-223 (Ra-223) in metastatic castration-resistant prostate cancer (mCRPC) remains challenging due to alternative options and short window of opportunity. Methods: Ra-223 treated patients in the CAPRI-registry were included. Outcomes were evaluated based on treatment line of Ra-223. Results: Out of 285 patients, 49% received Ra-223 in line ≥3. 51% completed six Ra-223 injections and 34% had a symptomatic skeletal event after first Ra-223 without differences between subgroups. After correction of known prognostic factors Ra-223 in line ≥3 (HR: 3.267; 95% CI: 1.689-6.317; p < 0.01) remained associated with worse OS. Conclusion: In the Netherlands, Ra-223 was mainly started as second or third mCRPC-treatment in 2014-2018. Later timing of Ra-223 did affect OS, but not treatment completion and occurrence of symptomatic skeletal events.

Original language	English
Pages (from-to)	1371-1384
Number of pages	14
Journal	Future Oncology
Volume	16
Issue number	19
DOIs	https://doi.org/10.2217/fon-2020-0039
Publication status	Published - 29 May 2020

Bibliographical note

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.2217/fon-2020-0039

Cite this

Kuppen, M. C. P., Westgeest, H. M., Van Der Doelen, M. J., Van Den Eertwegh, A. J. M., Coenen, J. L. L. M., Aben, K. K. H., Van Den Bergh, A. C. M., Bergman, A. M., Van Den Bosch, J., Celik, F., Hendriks, M. P., Lavalaye, J., Van Der Meer, S., Polee, M. B., Somford, D. M., Van Oort, I. M., Uyl-De Groot, C. A., & Gerritsen, W. R. (2020). Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer. Future Oncology, 16(19), 1371-1384. https://doi.org/10.2217/fon-2020-0039

@article{f28d6113b2c948d2b4bf904818fb828d,

title = "Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer",

abstract = "Aim: Timing of radium-223 (Ra-223) in metastatic castration-resistant prostate cancer (mCRPC) remains challenging due to alternative options and short window of opportunity. Methods: Ra-223 treated patients in the CAPRI-registry were included. Outcomes were evaluated based on treatment line of Ra-223. Results: Out of 285 patients, 49\% received Ra-223 in line ≥3. 51\% completed six Ra-223 injections and 34\% had a symptomatic skeletal event after first Ra-223 without differences between subgroups. After correction of known prognostic factors Ra-223 in line ≥3 (HR: 3.267; 95\% CI: 1.689-6.317; p < 0.01) remained associated with worse OS. Conclusion: In the Netherlands, Ra-223 was mainly started as second or third mCRPC-treatment in 2014-2018. Later timing of Ra-223 did affect OS, but not treatment completion and occurrence of symptomatic skeletal events. ",

author = "Kuppen, \{Malou C.P.\} and Westgeest, \{H.M. (Hans)\} and \{Van Der Doelen\}, \{Maarten J.\} and \{Van Den Eertwegh\}, \{Alphonsus J.M.\} and Coenen, \{Jules L.L.M.\} and Aben, \{Katja K.H.\} and \{Van Den Bergh\}, \{Alphons C.M.\} and Bergman, \{Andries M.\} and \{Van Den Bosch\}, Joan and Filiz Celik and Hendriks, \{Mathijs P.\} and Jules Lavalaye and \{Van Der Meer\}, Saskia and Polee, \{Marco B.\} and Somford, \{Diederik M.\} and \{Van Oort\}, \{Inge M.\} and \{Uyl-De Groot\}, \{Carin A.\} and Gerritsen, \{Winald R.\}",

note = "Publisher Copyright: {\textcopyright} 2020 ",

year = "2020",

month = may,

day = "29",

doi = "10.2217/fon-2020-0039",

language = "English",

volume = "16",

pages = "1371--1384",

journal = "Future Oncology",

issn = "1479-6694",

publisher = "Taylor \& Francis Ltd (UK)",

number = "19",

}

Kuppen, MCP, Westgeest, HM, Van Der Doelen, MJ, Van Den Eertwegh, AJM, Coenen, JLLM, Aben, KKH, Van Den Bergh, ACM, Bergman, AM, Van Den Bosch, J, Celik, F, Hendriks, MP, Lavalaye, J, Van Der Meer, S, Polee, MB, Somford, DM, Van Oort, IM, Uyl-De Groot, CA & Gerritsen, WR 2020, 'Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer', Future Oncology, vol. 16, no. 19, pp. 1371-1384. https://doi.org/10.2217/fon-2020-0039

TY - JOUR

T1 - Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer

AU - Kuppen, Malou C.P.

AU - Westgeest, H.M. (Hans)

AU - Van Der Doelen, Maarten J.

AU - Van Den Eertwegh, Alphonsus J.M.

AU - Coenen, Jules L.L.M.

AU - Aben, Katja K.H.

AU - Van Den Bergh, Alphons C.M.

AU - Bergman, Andries M.

AU - Van Den Bosch, Joan

AU - Celik, Filiz

AU - Hendriks, Mathijs P.

AU - Lavalaye, Jules

AU - Van Der Meer, Saskia

AU - Polee, Marco B.

AU - Somford, Diederik M.

AU - Van Oort, Inge M.

AU - Uyl-De Groot, Carin A.

AU - Gerritsen, Winald R.

PY - 2020/5/29

Y1 - 2020/5/29

N2 - Aim: Timing of radium-223 (Ra-223) in metastatic castration-resistant prostate cancer (mCRPC) remains challenging due to alternative options and short window of opportunity. Methods: Ra-223 treated patients in the CAPRI-registry were included. Outcomes were evaluated based on treatment line of Ra-223. Results: Out of 285 patients, 49% received Ra-223 in line ≥3. 51% completed six Ra-223 injections and 34% had a symptomatic skeletal event after first Ra-223 without differences between subgroups. After correction of known prognostic factors Ra-223 in line ≥3 (HR: 3.267; 95% CI: 1.689-6.317; p < 0.01) remained associated with worse OS. Conclusion: In the Netherlands, Ra-223 was mainly started as second or third mCRPC-treatment in 2014-2018. Later timing of Ra-223 did affect OS, but not treatment completion and occurrence of symptomatic skeletal events.

AB - Aim: Timing of radium-223 (Ra-223) in metastatic castration-resistant prostate cancer (mCRPC) remains challenging due to alternative options and short window of opportunity. Methods: Ra-223 treated patients in the CAPRI-registry were included. Outcomes were evaluated based on treatment line of Ra-223. Results: Out of 285 patients, 49% received Ra-223 in line ≥3. 51% completed six Ra-223 injections and 34% had a symptomatic skeletal event after first Ra-223 without differences between subgroups. After correction of known prognostic factors Ra-223 in line ≥3 (HR: 3.267; 95% CI: 1.689-6.317; p < 0.01) remained associated with worse OS. Conclusion: In the Netherlands, Ra-223 was mainly started as second or third mCRPC-treatment in 2014-2018. Later timing of Ra-223 did affect OS, but not treatment completion and occurrence of symptomatic skeletal events.

UR - https://www.scopus.com/pages/publications/85087110450

U2 - 10.2217/fon-2020-0039

DO - 10.2217/fon-2020-0039

M3 - Article

C2 - 32469606

AN - SCOPUS:85087110450

SN - 1479-6694

VL - 16

SP - 1371

EP - 1384

JO - Future Oncology

JF - Future Oncology

IS - 19

ER -

Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this